ExQor is developing a unique biologic to restore cognitive capabilities by regenerating neurons and their connections that have been damaged by neurodegenerative disorders, like Alzheimer's disease and frontotemporal dementia.
It is unlike other drugs that simply delay disease progression.
Treatments for multiple types of CNS disorders are possible using ExQor's biologic, including treating depression.
ExQor is preparing its first IND applications to FDA for treating cognitive impairments that are consequences of dementias.
A valley of uncertainty exists among those diagnosed with mild cognitive impairment or early Alzheimer's, or who have family members or relations who have or had Alzheimer's and are concerned whether they are also at risk.
ExQor has MRI and EEG diagnostic development programs underway for detecting and assessing early-stage Alzheimer's or identifying mild cognitive impairment (MCI) that could convert to Alzheimer's.
When used together with its new biologic, ExQor's new MRI and EEG tools and their companion AI systems would enable a significant step forward in global healthcare for dementias.ExQor has multiple allowed patents and patents pending.
© 2025 ExQor Technologies, Inc . All rights reserved
